Small-cap Healthcare company Madrigal Pharmaceuticals has moved 5.8% so far today on a volume of 1,890,576, compared to its average of 450,628. In contrast, the S&P 500 index moved 0.1%.
Madrigal Pharmaceuticals trades 63.04% away from its average analyst target price of $152.42 per share. The 12 analysts following the stock have set target prices ranging from $75 to $203, and on average have given Madrigal Pharmaceuticals a rating of buy.
Anyone interested in buying MDGL should be aware of the facts below:
-
Based on its trailing earning per share of -13.09, Madrigal Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -19.0 while the S&P 500 average is 15.97
-
MDGL has a forward P/E ratio of -16.8 based on its forward 12 month price to earnings (Eps) of $-14.83 per share
-
Its Price to Book (P/B) ratio is 16.1 compared to its sector average of 4.07
-
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.
-
Based in West Conshohocken, the company has 71 full time employees and a market cap of $4,248,629,248.
